• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.

作者信息

Schjesvold Fredrik H, Richardson Paul G, Facon Thierry, Alegre Adrián, Spencer Andrew, Jurczyszyn Artur, Sunami Kazutaka, Frenzel Laurent, Min Chang-Ki, Guillonneau Sophie, Lin Peggy L, Le-Guennec Solenn, Campana Frank, van de Velde Helgi, Bensfia Samira, Bringhen Sara

机构信息

Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Norway.

Dana-Farber Cancer Institute, Boston, MA.

出版信息

Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.

DOI:10.3324/haematol.2020.253450
PMID:32586908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8018100/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19f5/8018100/e3a4cd8588c0/1061182.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19f5/8018100/e3a4cd8588c0/1061182.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19f5/8018100/e3a4cd8588c0/1061182.fig1.jpg

相似文献

1
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性老年多发性骨髓瘤患者：ICARIA-MM亚组分析
Haematologica. 2021 Apr 1;106(4):1182-1187. doi: 10.3324/haematol.2020.253450.
2
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.isatuximab联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤虚弱患者：ICARIA-MM亚组分析
Am J Hematol. 2021 Nov 1;96(11):E423-E427. doi: 10.1002/ajh.26319. Epub 2021 Sep 23.
3
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤中isatuximab联合泊马度胺和地塞米松的预测生物标志物
Blood Cancer J. 2021 Mar 12;11(3):55. doi: 10.1038/s41408-021-00438-y.
4
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
5
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.依沙佐米昔单抗治疗复发/难治性多发性骨髓瘤：III 期 ICARIA-MM 研究关键亚组分析综述。
Future Oncol. 2021 Dec;17(34):4797-4812. doi: 10.2217/fon-2021-0568. Epub 2021 Sep 15.
6
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.依既往治疗线数和难治状态分层的复发/难治性多发性骨髓瘤患者中伊沙佐米联合泊马度胺和地塞米松治疗：ICARIA-MM 亚组分析。
Leuk Res. 2021 May;104:106576. doi: 10.1016/j.leukres.2021.106576. Epub 2021 Mar 29.
7
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.ICARIA-MM 研究中伴有高危细胞遗传学的复发/难治性多发性骨髓瘤患者的亚组分析。
Br J Haematol. 2021 Jul;194(1):120-131. doi: 10.1111/bjh.17499. Epub 2021 May 25.
8
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.isatuximab治疗的复发/难治性多发性骨髓瘤患者按1q21+状态划分的主要结局：来自ICARIA-MM和IKEMA的亚组分析
Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.
9
Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.依沙佐米-泊马度胺-地塞米松对比泊马度胺-地塞米松用于治疗东亚复发/难治性多发性骨髓瘤患者：ICARIA-MM 亚组分析。
Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e751-e761. doi: 10.1016/j.clml.2022.04.005. Epub 2022 Apr 8.
10
Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.五例既往接受抗 C38 达妥木单抗治疗的复发多发性骨髓瘤患者中抗-CD38 依沙妥昔单抗联合泊马度胺和地塞米松的疗效：病例系列。
Hematology. 2022 Dec;27(1):204-207. doi: 10.1080/16078454.2022.2028978.

引用本文的文献

1
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.《复发/难治性多发性骨髓瘤临床实践中基于抗CD38治疗的共识指南与建议：来自泛太平洋多发性骨髓瘤工作组》
Clin Hematol Int. 2025 Aug 8;7(3):36-59. doi: 10.46989/001c.141401. eCollection 2025.
2
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.复发难治性多发性骨髓瘤中的单克隆抗体
Pharmaceuticals (Basel). 2025 Jan 22;18(2):145. doi: 10.3390/ph18020145.
3
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

本文引用的文献

1
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
2
Insights into the management of older patients with multiple myeloma.老年多发性骨髓瘤患者管理的见解
Clin Adv Hematol Oncol. 2019 Jul;17(7):390-392.
3
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
isatuximab、泊马度胺和地塞米松作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验外270例患者的回顾性临床经验
Haematologica. 2025 Apr 1;110(4):1028-1033. doi: 10.3324/haematol.2024.286658. Epub 2024 Nov 28.
4
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.复发/难治性多发性骨髓瘤的难治性患者：临床试验结果综述
EJHaem. 2023 Aug 2;4(4):1117-1131. doi: 10.1002/jha2.743. eCollection 2023 Nov.
5
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma.如何管理来那度胺难治性多发性骨髓瘤患者。
Cancers (Basel). 2022 Dec 27;15(1):155. doi: 10.3390/cancers15010155.
6
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab.依沙替康单抗治疗多发性骨髓瘤：综述及与达雷妥尤单抗的比较。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221106563. doi: 10.1177/15330338221106563.
7
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.依沙佐米联合卡非佐米和地塞米松与卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤老年患者的疗效：IKEMA 亚组分析。
Hematol Oncol. 2022 Dec;40(5):1020-1029. doi: 10.1002/hon.3038. Epub 2022 Jun 8.
8
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.isatuximab联合泊马度胺和地塞米松治疗复发骨髓瘤的疗效：一项全英国真实世界数据集的结果
Hemasphere. 2022 May 26;6(6):e738. doi: 10.1097/HS9.0000000000000738. eCollection 2022 Jun.
9
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.基于泊马度胺和地塞米松的方案治疗难治性/复发性多发性骨髓瘤
Ther Adv Hematol. 2022 May 13;13:20406207221090089. doi: 10.1177/20406207221090089. eCollection 2022.
10
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.在多发性骨髓瘤患者中，与泊马度胺/地塞米松联合治疗时，进行暴露-反应分析以选择/确认伊沙妥昔单抗的最佳剂量方案。
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):766-777. doi: 10.1002/psp4.12789. Epub 2022 Apr 17.
抗 CD38 单克隆抗体伊沙妥昔单抗在多发性骨髓瘤中的作用机制。
Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28.
4
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.依沙替康单抗联合泊马度胺/地塞米松与泊马度胺/地塞米松治疗复发/难治性多发性骨髓瘤的 ICARIA Ⅲ期研究设计。
Future Oncol. 2018 May;14(11):1035-1047. doi: 10.2217/fon-2017-0616. Epub 2017 Dec 22.
5
CD38 antibodies in multiple myeloma: back to the future.多发性骨髓瘤中的 CD38 抗体：回到未来。
Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8.
6
Multiple myeloma in the very elderly patient: challenges and solutions.老年患者的多发性骨髓瘤：挑战与解决方案
Clin Interv Aging. 2016 Apr 15;11:423-35. doi: 10.2147/CIA.S89465. eCollection 2016.
7
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.SAR650984 通过溶酶体相关和凋亡途径直接诱导多发性骨髓瘤细胞死亡，而泊马度胺则进一步增强了这一作用。
Leukemia. 2016 Feb;30(2):399-408. doi: 10.1038/leu.2015.240. Epub 2015 Sep 4.
8
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
9
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.SAR650984，一种新型人源化 CD38 靶向抗体，在多发性骨髓瘤和其他 CD38+血液恶性肿瘤模型中显示出强大的抗肿瘤活性。
Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1.
10
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.年龄和器官损伤与骨髓瘤患者的生存不良相关：来自 4 项随机试验的 1435 名个体患者数据的荟萃分析。
Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.